Comparison of SP142 and 22C3 Immunohistochemistry PD-L1 Assays for Clinical Efficacy of Atezolizumab in Non–Small Cell Lung Cancer: Results From the Randomized OAK Trial - Clinical Lung Cancer
Selection of ongoing trials of pembrolizumab or atezolizumab in TNBC... | Download Scientific Diagram
Atezolizumab - Wikipedia
History of PD-1 research. Abbreviations: FIM, first in man; approved,... | Download Scientific Diagram
Atezolizumab plus Bevacizumab combination therapy compared to Sorafenib and Atezolizumab monotherapies for treatment of unresectable or metastatic hepatocellular carcinoma - Asian Pacific Digestive Week 2021 | Kuala Lumpur
IMPower133 Clinical Trial Design for ES-SCLC | TECENTRIQ® (atezolizumab)
Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial | Nature Medicine
FLASCO / Atezolizumab Clinical Trials
Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial - Journal of Thoracic Oncology
IMpower150, IMpower110, & OAK Clinical Trial Designs | TECENTRIQ® ( atezolizumab)
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma | NEJM
Profile of atezolizumab in the treatment of metastatic non-small-cell | DDDT
Atezolizumab for Urinary Bladder Cancer Clinical Trial | Power
Imugene Entered into a Clinical Trial Supply Agreement with Roche to Evaluate PD1-Vaxx + Atezolizumab for the Treatment of Lung Cancer
Atezolizumab Versus Docetaxel in Pretreated Patients With NSCLC: Final Results From the Randomized Phase 2 POPLAR and Phase 3 OAK Clinical Trials - Journal of Thoracic Oncology
Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial - The Lancet
Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial - The Lancet Oncology
Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC | NEJM
Atezolizumab Versus Chemotherapy in Patients with Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: A Long-term Overall Survival and Safety Update from the Phase 3 IMvigor211 Clinical Trial - European Urology
Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial - The Lancet
Ongoing clinical trials of PD-1 and PD-L1 inhibitors for lung cancer in China | Journal of Hematology & Oncology | Full Text
Overview of listed clinical trials for Atezolizumab, Nivolumab, and... | Download Scientific Diagram
